222 related articles for article (PubMed ID: 16952489)
21. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
22. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
[TBL] [Abstract][Full Text] [Related]
23. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
24. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
25. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
26. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
Zhang W; Tan TM; Lim LY
Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
[TBL] [Abstract][Full Text] [Related]
27. Sex differences in CYP3A activity using intravenous and oral midazolam.
Chen M; Ma L; Drusano GL; Bertino JS; Nafziger AN
Clin Pharmacol Ther; 2006 Nov; 80(5):531-8. PubMed ID: 17112809
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich V; Murakoso K; Sato H
Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
[TBL] [Abstract][Full Text] [Related]
29. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
30. Erythromycin breath test results in elderly, very elderly, and frail elderly persons.
Schwartz JB
Clin Pharmacol Ther; 2006 May; 79(5):440-8. PubMed ID: 16678546
[TBL] [Abstract][Full Text] [Related]
31. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice.
Farkas D; Oleson LE; Zhao Y; Harmatz JS; Zinny MA; Court MH; Greenblatt DJ
J Clin Pharmacol; 2007 Mar; 47(3):286-94. PubMed ID: 17322140
[TBL] [Abstract][Full Text] [Related]
32. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Isoherranen N; Ludington SR; Givens RC; Lamba JK; Pusek SN; Dees EC; Blough DK; Iwanaga K; Hawke RL; Schuetz EG; Watkins PB; Thummel KE; Paine MF
Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
[TBL] [Abstract][Full Text] [Related]
33. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis.
Kaneshiro Y; Oda Y; Iwakiri K; Masada T; Iwaki H; Hirota Y; Kondo K; Takaoka K
Clin Pharmacol Ther; 2006 Oct; 80(4):396-402. PubMed ID: 17015057
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
[TBL] [Abstract][Full Text] [Related]
35. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
[TBL] [Abstract][Full Text] [Related]
36. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
37. Effect of mibefradil on CYP3A4 in vivo.
Veronese ML; Gillen LP; Dorval EP; Hauck WW; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Oct; 43(10):1091-100. PubMed ID: 14517191
[TBL] [Abstract][Full Text] [Related]
38. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
Ring BJ; Patterson BE; Mitchell MI; Vandenbranden M; Gillespie J; Bedding AW; Jewell H; Payne CD; Forgue ST; Eckstein J; Wrighton SA; Phillips DL
Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
[TBL] [Abstract][Full Text] [Related]
39. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
Teng R; Butler K
Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
[TBL] [Abstract][Full Text] [Related]
40. The erythromycin breath test predicts the clearance of midazolam.
Lown KS; Thummel KE; Benedict PE; Shen DD; Turgeon DK; Berent S; Watkins PB
Clin Pharmacol Ther; 1995 Jan; 57(1):16-24. PubMed ID: 7828377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]